Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Front-line Clear all

Conditions: Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Interventions: brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more

Conditions: Pancreatic Cancer
Interventions: MM-141, Placebo, Gemcitabine, Nab-Paclitaxel; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 47
States / cities: Gilbert, Arizona • Anaheim, California • Fullerton, California + 40 more

Conditions: Advanced Metastatic Melanoma
Interventions: Cabozantinib, Pembrolizumab; Drug
Lead sponsor: John Rieth; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Colorectal Cancer
Interventions: Tivantinib, Placebo, Cetuximab, Irinotecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 24
States / cities: Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more

Conditions: Metastatic Pancreatic Cancer
Interventions: FOLFIRINOX; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Large-Cell Neuroendocrine Carcinoma
Interventions: Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma, Treatment for Small Cell Lung Cancer; Other
Lead sponsor: Charles Kunos; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Lymphoma, Marginal Zone Lymphoma, MZL
Interventions: Venetoclax, Rituximab; Drug
Lead sponsor: Gottfried von Keudell, MD PhD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma Multiforme
Interventions: Axitinib, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Cincinnati; Other
Eligibility: 70 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Prostate Cancer
Interventions: Abraxane; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Vallejo, California

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Venetoclax, Zanubrutinib; Procedure · Drug
Lead sponsor: Kerry Rogers; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI); Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 60 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Atlanta, Georgia + 11 more

Conditions: Follicular Lymphoma
Interventions: Rituximab, Neo Vax, Pembrolizumab; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Lenalidomide, Peripheral Blood Stem Cell Transplantation, Prednisone, Vincristine Sulfate; Procedure · Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: Duarte, California • Palo Alto, California • Aurora, Colorado + 5 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Sotorasib, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 27
States / cities: Santa Barbara, California • Newark, Delaware • Coral Springs, Florida + 23 more

Conditions: Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma
Interventions: Enfortumab vedotin, Pembrolizumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg; Drug · Biological · Dietary Supplement
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more

Conditions: Marginal Zone Lymphoma
Interventions: Rituximab, Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 8
States / cities: Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Interventions: MM-111, Paclitaxel, Trastuzumab; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more

Conditions: Lung Cancer
Interventions: Carboplatin, Pemetrexed, Bevacizumab, Cixutumumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Treatment Free Observation; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Monroe, North Carolina • Philadelphia, Pennsylvania

Conditions: Hairy Cell Leukemia
Interventions: Low dose vemurafenib plus rituximab; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
Interventions: Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine; Drug · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • Duarte, California • San Diego, California + 12 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Avelumab, Chemoradiation; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 139
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more

Conditions: Hodgkin Lymphoma
Interventions: doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more

Search by objective public record fields.

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)